Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT01318642 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped NCT01318642: Planned independent DMC Interim review: ended for futility

Conditions

Adenocarcinoma of the Pancreas
Locally Advanced
Unresectable

Interventions

DRUG: Gemcitabine
DRUG: AMG 479
DRUG: Placebo

Sponsor

NantBioScience, Inc.